ABSTRACT
The intestinal microbiome influences growth and disease progression in children with cystic fibrosis (CF). Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA), the newest pharmaceutical modulator for CF, restores function of the pathogenic mutated CFTR channel. We performed a single-center longitudinal analysis of the effect of ELX/TEZ/IVA on the intestinal microbiome, intestinal inflammation, and clinical parameters in children with CF. Following ELX/TEZ/IVA, children with CF had significant improvements in BMI, ppFEV1 and required fewer antibiotics for respiratory infections. Intestinal microbiome diversity increased following ELX/TEZ/IVA coupled with a decrease in the intestinal carriage of Staphylococcus aureus, the predominant respiratory pathogen in children with CF. There was a reduced abundance of microbiome-encoded antibiotic-resistance genes. Microbial pathways for aerobic respiration were reduced after ELX/TEZ/IVA. The abundance of microbial acid tolerance genes was reduced, indicating microbial adaptation to increased CFTR function. In all, this study represents the first comprehensive analysis of the intestinal microbiome in children with CF receiving ELX/TEZ/IVA.
IMPORTANCE Cystic fibrosis is an autosomal recessive disease with significant gastrointestinal symptoms in addition to pulmonary complications. Prior work has shown that the intestinal microbiome correlates with health outcomes in CF, particularly in children. Recently approved treatments for CF, CFTR modulators, are anticipated to substantially improve the care of patients with CF and extend their lifespans. Here, we study the intestinal microbiome of children with CF before and after the CFTR modulator, ELX/TEZ/IVA. We identify promising improvements in microbiome diversity, reduced measures of intestinal inflammation, and reduced antibiotic resistance genes. We present specific bacterial taxa and protein groups which change following ELX/TEZ/IVA. These results will inform future mechanistic studies to understand the microbial improvements associated with CFTR modulator treatment. This study demonstrates how the microbiome can change in response to a targeted medication that corrects a genetic disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported, in part, by National Institutes of Health (NIH) grants T32DK007673 (RB), K23AI156132 (MRN), F30AI169748 (SAR), T32GM007347 (SAR), and P30DK089507 (SJS); the Cystic Fibrosis Foundation (SINGH19R0 to SJS) and the Thrasher Research Fund (RB and MRN).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Monroe Carell Jr. Children's Hospital at Vanderbilt (MCJCHV) Institutional Review Board (IRB # 200396).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revised in response to reviewer comments. Figures have been rearranged. Discussion section is expanded
Data Availability
All sequence data derived from this work are publicly available in NCBI-Genbank databases under Bioproject PRJNA948536. All processed data and code used for bioinformatic analysis is available within the repository: https://github.com/reaset41/CF-GI-Microbiome-ELX-TEZ-IVA.
